{"analyses":[{"ciLowerLimit":"0.695","ciNumSides":"TWO_SIDED","ciPctValue":"90","ciUpperLimit":"0.886","groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY","paramType":"Ratio of Least square mean","paramValue":"0.785"}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"403.35","value":"803.7"},{"groupId":"OG001","spread":"228.57","value":"582.1"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"16"},{"groupId":"OG001","value":"15"}],"units":"Participants"}],"description":"Blood samples were collected at indicated time points to analyze the maximum observed plasma concentration of niraparib.","dispersionType":"Standard Deviation","groups":[{"description":"Participants received Niraparib 300 mg in fasted condition","id":"OG000","title":"FE Niraparib Fasted"},{"description":"Participants received Niraparib 300 mg in fed condition","id":"OG001","title":"FE Niraparib Fed"}],"paramType":"MEAN","populationDescription":"Pharmacokinetic population. Only those participants with data available at the specified time points were analyzed.","reportingStatus":"POSTED","timeFrame":"Pre-dose (Day -1) and at 1, 1.5, 2, 3, 4, 6, 8, 12, 24, 48, 72, 96, 120 hours post dose","title":"Maximum Observed Plasma Concentration (Cmax) Following Administration of Niraparib (FE Sub-study)","type":"SECONDARY","unitOfMeasure":"Nanograms per milliliter"}